Polypropylene Mesh
Polypropylene (PP) is a permanent synthetic mesh used in midurethral slings for stress urinary incontinence (SUI) and abdominal sacrocolpopexy for apical pelvic organ prolapse (POP). A sling, an abdominal prolapse mesh and a transvaginal POP mesh are different devices and procedures. Their evidence and regulatory status must be discussed separately.[1]
This is the material hub. For selection and operative management, see Female SUI, Prolapse Repair and Mesh Complications.
Material Properties
Modern pelvic-floor PP devices commonly use macroporous monofilament mesh; NICE specifies type 1 macroporous PP for retropubic midurethral slings. Porosity, filament structure, weight, stiffness and deformation all matter. A pore-size threshold is not a guarantee against bacterial colonization, exposure or pain.[2][3]
PP is not biologically inert: implantation produces a tissue response, and the vaginal environment differs from the abdominal wall. Claims that PP degradation has been definitively disproved are too strong. One explant study attributed apparent surface cracking to removable protein/fixation artifacts, whereas subsequent materials literature continues to describe possible in-vivo degradation. Neither position establishes an individual patient's cause of pain or predicts failure from an explant image alone.[3][4][5]
Lighter mesh is not automatically a safer interchangeable device. Page's 2023 sacrocolpopexy study compared consecutive prospective cohorts, including a lightweight partially absorbable PP/poliglecaprone product. Long-term graft-related complications were 13/178 (7.3%) versus 23/101 (22.8%); graft-related reinterventions were 5/238 (2.1%) versus 19/101 (18.8%). Different outcome denominators and nonrandom allocation limit causal attribution to weight alone.[6]
Evidence by Operation
| Application | Clinically useful interpretation |
|---|---|
| Midurethral sling for SUI | AUA/SUFU includes retropubic, transobturator and single-incision slings among options for appropriately evaluated index patients, alongside autologous fascia, Burch colposuspension and bulking. Discuss permanent-mesh risks and alternatives before selection.[7] |
| Retropubic versus transobturator sling | The 2017 Cochrane review found broadly similar short-term subjective cure. Retropubic placement had more bladder perforation and voiding dysfunction; transobturator placement had more groin pain. Long-term retreatment comparisons were less certain; avoid one route-wide cure percentage.[8] |
| Single-incision sling | FDA's April 2024 assessment found comparable effectiveness and adverse-event types/rates to traditional MUS through 36 months. The 2023 Cochrane review supports similar 12-month efficacy versus transobturator slings, while retropubic comparisons and longer-term outcomes remain less certain.[1][9] |
| Abdominal sacrocolpopexy | Remains a distinct mesh application outside the FDA transvaginal POP order. Product, concomitant procedures and length of follow-up affect exposure risk; vaginal POP-kit complication rates cannot simply be transferred to sacrocolpopexy.[1][6] |
| Transvaginal permanent mesh for POP | In the 2024 Cochrane review, lower prolapse awareness and repeat prolapse surgery were offset by more total repeat surgery for prolapse, SUI or exposure (RR 1.56, 95% CI 1.07–2.26), bladder injury and de novo SUI. Exposure was 11.8%, with 6.1% undergoing exposure surgery. These are POP-mesh data, not MUS estimates.[10] |
A large English administrative cohort of 95,057 women found estimated 9-year risks of 3.3% for sling removal, 4.5% for further SUI surgery and 6.9% for either. These overlapping outcomes are not additive, and reoperation does not capture every symptomatic complication.[11]
Safety and Complication Assessment
AUA/SUFU advises against synthetic sling placement after intraoperative urethral injury, or concurrently with urethral diverticulectomy, urethrovaginal fistula repair or urethral mesh excision. Strongly consider mesh alternatives with radiation injury, substantial scarring or poor tissue quality.[7]
Potential problems include vaginal exposure, urinary-tract perforation, infection, voiding dysfunction, recurrent incontinence, urgency, pain and dyspareunia. A percentage from a specialist mesh-complication referral series is not the incidence among all implant recipients. Mesh removal may itself cause injury or recurrent prolapse/incontinence and may not resolve pain.[2][8]
NICE's management framework includes:[2]
- For a single vaginal exposure smaller than 1 cm², discuss topical vaginal estrogen and review within 3 months.
- Consider vaginal mesh removal for larger exposure, extrusion, failure of conservative treatment or the patient's informed preference; the extent of removal requires individualized counseling.
- Refer urinary-tract perforation or complex symptoms to a specialist mesh service. Persistent pain without an identified mesh abnormality can require pelvic-floor, pain and other multidisciplinary treatment rather than automatic complete excision.
An asymptomatic recipient does not need preventive removal solely because a mesh product was withdrawn. New bleeding, discharge, pain, dyspareunia, infection or voiding symptoms warrants evaluation.[12]
Regulatory Distinctions
| Jurisdiction | Scope |
|---|---|
| United States | FDA's April 2019 order stopped sale/distribution of the remaining transvaginal POP products. It did not remove SUI slings or abdominal POP mesh.[1] |
| Australia | TGA cancelled transvaginal POP meshes and single-incision mini-slings in 2017. Its current information explicitly distinguishes standard midurethral slings and abdominally placed prolapse mesh, which remain available. Australia did not ban every MUS.[13] |
| England / NICE guidance | The 2018 high-vigilance restriction allowed specified exceptions; it was not a permanent, uniform UK-wide ban on all mesh. NICE recommendations differ from AUA's in route selection and use of single-incision slings; current local restrictions also apply.[2][14] |
Record the exact implant and route. Brand family, material name or a generic hernia indication does not establish suitability for a different pelvic-floor operation.
See also: Absorbable Mesh, Coated / Hybrid Mesh, Autologous Rectus Fascia.
References
1. US Food and Drug Administration. FDA Activities: Urogynecologic Surgical Mesh. Includes April 2024 SUI mini-sling review and 2019 POP order.
2. NICE. Urinary incontinence and pelvic organ prolapse in women: management (NG123). Sections 1.5 and 1.11; current online recommendations accessed September 2026.
3. Abhari RE, Izett-Kay ML, Morris HL, Cartwright R, Snelling SJB. Host-Biomaterial Interactions in Mesh Complications After Pelvic Floor Reconstructive Surgery. Nature Reviews Urology. 2021;18(12):725-738. doi:10.1038/s41585-021-00511-y
4. Thames SF, White JB, Ong KL. The Myth: In Vivo Degradation of Polypropylene-Based Meshes. International Urogynecology Journal. 2017;28(2):285-297. doi:10.1007/s00192-016-3131-4
5. Jain T, Isayeva IS, Simon DD. Polypropylene Surgical Mesh Implants for Hernia and Pelvic Floor Disorders: A Materials Performance Perspective. Journal of Biomedical Materials Research Part A. 2025;113(8):e37970. doi:10.1002/jbm.a.37970
6. Page AS, Cattani L, Pacquée S, et al. Long-Term Data on Graft-Related Complications After Sacrocolpopexy With Lightweight Compared With Heavier-Weight Mesh. Obstetrics and Gynecology. 2023;141(1):189-198. doi:10.1097/AOG.0000000000005021
7. AUA/SUFU. Surgical Treatment of Female Stress Urinary Incontinence: 2023 guideline. Statements 10, 12–14 and 17–18.
8. Ford AA, Rogerson L, Cody JD, Aluko P, Ogah JA. Mid-Urethral Sling Operations for Stress Urinary Incontinence in Women. Cochrane Database of Systematic Reviews. 2017;7:CD006375. doi:10.1002/14651858.CD006375.pub4
9. Carter E, Johnson EE, Still M, et al. Single-Incision Sling Operations for Urinary Incontinence in Women. Cochrane Database of Systematic Reviews. 2023;10:CD008709. doi:10.1002/14651858.CD008709.pub4
10. Yeung E, Baessler K, Christmann-Schmid C, et al. Transvaginal Mesh or Grafts or Native Tissue Repair for Vaginal Prolapse. Cochrane Database of Systematic Reviews. 2024;3:CD012079. doi:10.1002/14651858.CD012079.pub2
11. Gurol-Urganci I, Geary RS, Mamza JB, et al. Long-term Rate of Mesh Sling Removal Following Midurethral Mesh Sling Insertion Among Women With Stress Urinary Incontinence. JAMA. 2018;320(16):1659-1669. doi:10.1001/jama.2018.14997
12. US Food and Drug Administration. Pelvic Organ Prolapse (POP). Advice for existing mesh recipients.
13. Therapeutic Goods Administration. About transvaginal surgical mesh devices. Updated December 19, 2023.
14. UK Department of Health and Social Care. Government announces strict rules for the use of vaginal mesh. July 10, 2018.